SCHEMBL26412341

SCHEMBL26412341

COC(=O)c1cc(CCc2cc(O[Si](c3ccccc3)(c3ccccc3)C(C)(C)C)c3ccc(Cl)cc3c2)n(C)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.38
EGFR P00533 1/20 0.33
MRGPRX4 Q96LA9 4/20 0.33
MAPT P10636 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
GAA P10253 1/20 0.32
PTGER1 P34995 1/20 0.32
KMT2A Q03164 2/20 0.32
TP53 P04637 2/20 0.31
LMNA P02545 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
MDM2 Q00987 1/20 0.31
ADCY10 Q96PN6 1/20 0.31
DRD2 P14416 1/20 0.31
TBXA2R P21731 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26414162 0.91 ALDH1A1 (0.33) PLA2G2AKMT2AMEN1
SCHEMBL25934603 0.90 PLA2G2A (0.38) PLA2G2AKMT2ALMNAMEN1
SCHEMBL26020504 0.86 MEN1 (0.32) PLA2G2AKMT2AMEN1NPC1RAB9A
SCHEMBL26412454 0.85 NOTUM (0.33) PLA2G2AKMT2AMEN1NPC1RAB9A
SCHEMBL26412344 0.84 PLA2G2A (0.31) PLA2G2A
SCHEMBL26412345 0.84 CYP3A4 (0.31)
SCHEMBL26412339 0.81 HSD17B10 (0.34) PLA2G2AEGFRMRGPRX4MAPTKMT2A
SCHEMBL26415363 0.80 PLA2G2A (0.39) PLA2G2AEGFRMRGPRX4MAPTGAA
SCHEMBL26412332 0.77 LTB4R (0.33) PLA2G2AMRGPRX4PTGER1KMT2A
SCHEMBL24073863 0.76 MEN1 (0.36) PLA2G2AMAPTGAAKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-04-27 US disclosed
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 MCL1, BCL2L1, BAK1 PLA2G2A 3383/4885EGFR 1698/4885MRGPRX4 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.